Ubiquitin--Proteasome System and Cancer
=======================================

In order to maintain cellular homeostasis, the amount of proteins in cells is selectively controlled not only in protein synthesis but also in protein degradation. The ubiquitin--proteasome pathway is essential for multiple physiological systems via selective degradation of target proteins (Hershko and Ciechanover, [@B43]). The proteins designated for proteasome-mediated degradation are conjugated with polypeptide of ubiquitin, which are then targeted to 26S proteasome complex (Hochstrasser, [@B44]). Ubiquitination of target protein is regulated through multi-enzyme processes in an ATP-dependent manner. First, the E1 protein, ubiquitin-activating enzyme, activates ubiquitin, which is then transferred to the E2 protein. The E3 protein is an ubiquitin protein ligase that determines the substrate specificity. The RING finger-containing E3 ligase binds to its substrate and the ubiquitinated E2 protein and then directly transfers the ubiquitin from the E2 protein to the substrate (Lipkowitz and Weissman, [@B65]). On the other hand, the HECT domain-containing E3 ligase can also receive ubiquitin from the E2 protein first through an active-site cysteine of its HECT domain then interacts with its substrate to catalyze the conjugation of the activated ubiquitin to the substrate (Kee and Huibregtse, [@B55]). Since the specificity of the target proteins for proteasome-mediated degradation is dependent on the interaction between the E3 ligases and their targets, the E3 ubiquitin ligases are critical for regulating the expression levels of key short-lived proteins.

Cancer is a genetic disease that is caused by multiple genetic mutations. In cancer cells, oncogenic drivers that are frequently mutated or overexpressed activate the signaling pathways to promote cell proliferation, growth, and survival while tumor suppressors that are commonly inactivated by mutation or deletion inhibit these pathways. It has been demonstrated that the expression levels of some key oncoproteins and tumor suppressors are under the control of ubiquitin--proteasome system with some E3 ligases that function as oncogenic factors or tumor suppressors. For example, MDM2 and Skp2 ubiquitinate and inhibit tumor suppressors via proteasomal degradation, and thereby function as oncogenic factors (Marine and Lozano, [@B69]; Wang et al., [@B103]). In contrast, other E3 ligases such as the anaphase promoting complex/cyclosome (APC/C) and F-box and WD repeat domain-containing 7 (FBW7) serve as tumor suppressors by downregulating oncogenic factors (Crusio et al., [@B25]; Wasch et al., [@B104]).

Accumulating evidence indicates that ubiquitin--proteasome pathways are potential drug targets for cancer therapy. For example, bortezomib is a specific proteasome inhibitor that is currently used for the treatment of multiple myeloma. Moreover, the inhibitors for specific E3 ligases have been also considered as potential anti-cancer drugs. MDM2 is the primary ubiquitin ligase for tumor suppressor protein, p53, which induces apoptosis or senescence in response to oncogenic stress or DNA damage. The p53 pathway is frequently inactivated in human cancer cells, and the small molecules that block the interaction between p53 and MDM2 to inhibit p53 degradation have been tested in clinical trials (Brown et al., [@B13]). Therefore, dissecting the specific ubiquitin--proteasome signaling facilitating cancer progression may contribute to the development of novel drug targets.

Three Survival Kinases and Their Signaling Pathways
===================================================

Protein kinases and phosphatases catalyze the protein phosphorylation and dephosphorylation, respectively, which are essential for maintaining signal transduction. When cells receive extracellular signaling and stress, the signals are primarily transduced to the nucleus via protein phosphorylation, resulting in the alteration of gene expression. For example, epidermal growth factor (EGF) stimulates cell proliferation by binding to its receptor, EGF receptor (EGFR), and activating it. EGFR is a receptor tyrosine kinase that phosphorylates and activates multiple downstream targets and promotes cell growth and survival. EGFR, considered as an oncogene, is frequently overexpressed or mutated in multiple human cancers and promotes tumor progression, metastasis, and drug resistance (Nicholson et al., [@B74]; Hynes and Lane, [@B49]; Quatrale et al., [@B84]). Indeed, many oncoproteins include protein kinases, and these oncogenic kinases phosphorylate downstream targets to promote tumor growth, metastasis, and/or angiogenesis.

The serine/threonine kinase AKT is one of the major downstream kinases activated by growth factor signaling such as EGFR, platelet-derived growth factor receptor (PDGFR), and insulin-like growth factor receptor (IGFR). AKT has three isoforms, AKT1, AKT2, and AKT3, and their activities are frequently elevated in multiple human cancers, which contribute to cancer cell survival and growth (Altomare and Testa, [@B4]). AKT is activated by phosphatidylinositol-3 kinase (PI3K) that converts phosphatidylinositol (3,4)-bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-trisphosphate (PIP3) in plasma membrane through lipid phosphorylation (Altomare and Testa, [@B4]; Yuan and Cantley, [@B112]). AKT and phosphoinositide dependent kinase 1 (PDK1) are then recruited to the plasma membrane where AKT is directly phosphorylated and activated by PDK1 (Chan et al., [@B19]). Activated AKT phosphorylates various substrates involved in cell metabolism (GSK3, TSC2), survival (Bad, FOXO), and cell cycles (p21, p27, MDM2; Cross et al., [@B24]; Datta et al., [@B26]; Brunet et al., [@B14]; Zhou et al., [@B115],[@B116]; Liang et al., [@B61]; Manning et al., [@B68]), and then inhibits apoptosis and promotes cell growth. Therefore, the PI3K--AKT pathway is a potential drug target, and several PI3K or AKT inhibitors have been actively tested in numerous clinical trials (Garcia-Echeverria and Sellers, [@B38]; Wong et al., [@B106]; Chappell et al., [@B20]).

Extracellular signal-regulated kinase (ERK) is another critical downstream kinase in growth factor signaling and plays an essential role in cancer cell proliferation (Robinson and Cobb, [@B85]; Sebolt-Leopold, [@B86]). The Ras--Raf--MEK--ERK pathway is a well-characterized signaling pathway and is commonly activated in multiple human cancers. Studies have shown that Ras and Raf are frequently mutated in various human cancer types and responsible for cancer progression (Adjei, [@B2]; Davies et al., [@B28]). Therefore, this signaling pathway has been considered a drug target for cancer therapy, and a variety of inhibitors have been developed, including MEK or Raf inhibitors (Davies et al., [@B27]; Bollag et al., [@B10]; Hatzivassiliou et al., [@B40]; Maurer et al., [@B70]).

IκB kinases (IKKs) are the primary regulator of NF-κB, which plays a key role in immune response, cell proliferation, and survival (Baldwin, [@B7]; Luo et al., [@B67]). IKKs are activated in response to various cytokines and inflammatory stimuli such as tumor necrosis factor (TNF)-α, interleukin-1, and lipopolysaccharide. The IKK family includes IKKα, IKKβ, IKKγ, IKKε, and TANK-binding kinase 1 (TBK1). Interestingly, IKKγ has no kinase activity and functions as an adaptor protein for the canonical IKK complex (Hacker and Karin, [@B39]). IKKs are involved in two distinct pathways for NF-κB activation: the canonical and non-canonical pathways. IKKβ plays a dominant role in the canonical pathway and IKKα in the non-canonical pathway (Perkins, [@B81]; Israel, [@B52]). In the canonical pathway, IKKα, IKKβ, and IKKγ form a kinase complex that phosphorylates IκBα, an inhibitor protein of NF-κB, and induces the ubiquitination and subsequent proteasome-dependent degradation of IκBα. In the non-canonical pathway, IKKα forms a homodimer and phosphorylates p100, and generates p52 by partial processing of p100, resulting in the activation of p52/RelB. In contrast to IKKα and IKKβ, IKKε and TBK1 play a role in the induction of interferon signaling in response to viral infection (Shen and Hahn, [@B89]). Although NF-κB has been known to be involved in the progression of various cancers, increasing evidence suggests that IKKs also play vital roles in cancer independently of NF-κB (Lee and Hung, [@B58]; Baud and Karin, [@B8]; Shen and Hahn, [@B89]). For example, IKKα phosphorylates both estrogen receptor α (ERα) and co-activator SRC3 and enhances ERα transcriptional activity while IKKβ phosphorylates a tumor suppressor, tuberous sclerosis 1 (TSC1), and inhibits its function (Park et al., [@B79]; Lee et al., [@B59]). IKKα also phosphorylates CBP and the phosphorylated CBP preferentially interacts with NF-κB rather than p53, resulting in NF-κB activation as well as p53 inactivation (Huang et al., [@B47]). Recently, we found that IKKα phosphorylates and inhibits FOXA2. Inactivation of FOXA2 results in the decrease of NUMB expression, and subsequent NOTCH activation (Liu et al., [@B66]). Considering that inhibition of NF-κB may affect inflammatory responses, IKKs may be the potential alternative drug targets for cancer.

The above-mentioned three survival kinases play critical roles in cancer cell survival, metabolism, proliferation, and growth. Interestingly, these kinases have many common targets that they directly or indirectly regulate. Moreover, we and others have identified several common targets of these three kinases that are regulated by the ubiquitin--proteasome system. We will discuss these proteins one by one in the later next section of the review.

Forkhead Box O
==============

The forkhead box O (FOXO) family proteins are critical transcription factors that are involved in the regulation of cell proliferation, cell death, cell metabolism, and DNA repair (Tran et al., [@B97]; Arden, [@B5]). FOXO family includes FOXO1, FOXO3, FOXO4, and FOXO6, and is conserved from *C. elegans* to mammals (Burgering, [@B15]; Calnan and Brunet, [@B17]). FOXO family proteins directly activate multiple gene expression involved in cell cycles, apoptosis, metabolism, and DNA damage repair, such as p27kip, Bim, FasL, MnSOD, GADD45 (Dijkers et al., [@B31]; Kops et al., [@B56]; Tran et al., [@B96]; Ciechomska et al., [@B22]; Sunters et al., [@B93]). Moreover, it has been shown that FOXO proteins are dysregulated in multiple human cancers such as breast, prostate, leukemia, and glioblastoma (Hu et al., [@B45]; Seoane et al., [@B87]; Cornforth et al., [@B23]; Jagani et al., [@B53]). Conditional knockout mice of FOXO1, 3, and 4 develop thymic lymphomas and hemangiomas (Paik et al., [@B78]; Tothova et al., [@B95]). Therefore, FOXO is believed to function as a potential tumor suppressor.

It has been shown that IKK, AKT, and ERK directly phosphorylate FOXO and induce FOXO ubiquitination and degradation. Among the three kinases, AKT was first identified as a FOXO kinase that phosphorylates FOXO3 at T32, S253, and S315. Phosphorylated FOXO3 protein is excluded from entering the nucleus and binds to 14-3-3 in the cytoplasm (Brunet et al., [@B14]). In addition to FOXO3, FOXO1, and FOXO4 are also phoshorylated by AKT (Tzivion et al., [@B99]). AKT-phosphorylated FOXO1 and FOXO3 then undergo degradation in a proteasome-dependent manner (Plas and Thompson, [@B83]). Specifically, FOXO1 phosphorylated by AKT translocates to the cytosol where it is ubiquitinated by Skp2 and subjected to proteasome-dependent degradation (Huang et al., [@B46]). We found that IKKβ directly phosphorylates FOXO3 at S644 and induces its ubiquitination and degradation (Hu et al., [@B45]). Recently, E3 ligase β-transducing repeat-containing protein (β-TrCP) is reported to interact with FOXO3 and induces ubiquitination and degradation in an IKKβ-mediated-phosphorylation-dependent manner (Tsai et al., [@B98]; Su et al., [@B92]). Furthermore, we and others demonstrated that ERK phosphorylates FOXO3 and FOXO1, respectively (Asada et al., [@B6]; Yang et al., [@B110]). We also showed that FOXO3 is phosphorylated by ERK at S294, S344, and S425, which then undergoes MDM2-mediated ubiquitination, followed by proteasome-dependent degradation (Yang et al., [@B110]). MDM2-mediated ubiquitination and degradation is also observed with FOXO1, which is dependent on the AKT-mediated phosphorylation (Fu et al., [@B37]). Interestingly, MDM2 induces mono-ubiquitination of FOXO4, which promotes nuclear localization of FOXO4, and subsequent polyubiquitination by Skp2 and degradation (Brenkman et al., [@B12]). Taken together, the ubiquitin--proteasome system plays an essential role in regulating FOXO transcription factors by AKT, ERK, and IKK, and MDM2, SKP2, and βTrCP are E3 ligases for FOXO ubiquitination (Figure [1](#F1){ref-type="fig"}A).

![**Regulation of FOXO3 and β-catenin by AKT, ERK, and IKK signaling pathway**. **(A)** AKT, ERK, and IKK phosphorylates FOXO3 at different sites and induces its ubiquitination and subsequent degradation via SKP2, MDM2, and β-TrCP, respectively. **(B)** AKT and ERK phosphorylates GSK3β and inhibit it. GSK3β phosphorylates catenin and induces its ubiquitination and subsequent degradation via β-TrCP. Both AKT and IKKα phosphorylate β-catenin and stabilize it.](fonc-02-00015-g001){#F1}

β-Catenin
=========

β-Catenin is the key protein in both cadherin junction and Wnt pathway and plays an important role in development and adult homeostasis as well as tumorigenesis (Cadigan, [@B16]; Stepniak et al., [@B91]). In the Wnt signaling pathway, β-catenin functions as a transcription co-factor and is involved in the transactivation of several oncogenic proteins such as c-Myc, CyclinD1, and matrix metalloproteases (He et al., [@B41]; Lin et al., [@B63]; Mosimann et al., [@B73]). Glycogen synthase kinase-3β (GSK3β) and casein kinase 1 (CK1) are the major protein kinases regulating the β-catenin stability. In the absence of Wnt ligand, β-catenin forms a complex with Axin, APC, GSK3β, and CK1 and is phosphorylated by these kinases. Once phosphorylated, β-catenin undergoes β-TrCP-mediated ubiquitination and subsequent degradation. When Wnt binds to its receptor, Frizzles, and co-receptor, LRP5/6, the receptor complex recruits Axin--GSK3 complex to cell membrane, releasing β-catenin from the complex for its translocation to the nucleus where it activates gene transcription with T-cell factor (TCF) and lymphocyte enhancer factor (LEF).

AKT has been shown to directly phosphorylate GSK3β and inhibits it (Cross et al., [@B24]), and therefore, AKT seems to indirectly inhibit β-catenin degradation and inactivation through inhibition of GSK3β (Monick et al., [@B72]). In addition to the indirect mechanism, AKT directly mediates the β-catenin stability by phosphorylating β-catenin at S552. Once phosphorylated by AKT, β-catenin binds to 14-3-3ζ and is stabilized (Tian et al., [@B94]; Fang et al., [@B36]). In addition to AKT, we also demonstrated that ERK upregulates β-catenin via inhibition of GSK3β (Ding et al., [@B34]). Activated ERK directly interacts with GSK3β and phosphorylates it at T43. After the phosphorylation by ERK, GSK3 is primed for subsequent phosphorylation by p90RSK at S9, which inactivates it. Furthermore, IKK has been shown to be directly involved in the β-catenin regulation, and IKKα but not IKKβ phosphorylates β-catenin and prevent its ubiquitination and degradation (Lamberti et al., [@B57]; Albanese et al., [@B3]; Carayol and Wang, [@B18]). Collectively, β-catenin is another common target of AKT, ERK, and IKK, demonstrating that the ubiquitin--proteasome system plays a critical role in these signaling pathways (Figure [1](#F1){ref-type="fig"}B).

Myeloid Cell Leukemia-1
=======================

Myeloid cell leukemia-1 (Mcl-1) is a member of anti-apoptotic Bcl-2 family proteins which are the central regulators of apoptosis signaling pathway (Inuzuka et al., [@B50]). The Bcl-2 family consist of pro-apoptotic and anti-apoptotic proteins that regulate the release of apoptogenic proteins such as cytochrome *c* and Smac from mitochondria (Youle and Strasser, [@B111]). Pro-apoptotic Bcl-2 family proteins include the BH3-only proteins such as Bim, Bid, Bik, and Bad and multi-BH domain like Bax and Bak. Bax and Bak are able to form channels on the surface of mitochondria from which cytochrome *c* and Smac are released. Anti-apoptotic Bcl-2 family proteins, which include Bcl-2, Bcl-XL, and Mcl-1, prevent apoptotic cell death by inhibiting the activation and channel formation of Bax and Bak. In contrast, the BH3-only proteins directly bind to anti-apoptotic Bcl-2 family proteins and inhibit their functions. Thus, the balance of anti-apoptotic and pro-apoptotic proteins determines cell survival and death, and the expression of anti-apoptotic Bcl-2 family protein is the critical for cell survival. Among the anti-apoptotic Bcl-2 family proteins, Mcl-1 has a relatively short protein half-life (Nijhawan et al., [@B76]; Adams and Cooper, [@B1]) but its expression is enhanced in various cancer types (Placzek et al., [@B82]). Thus, Mcl-1 is an important survival factor in human cancer.

The primary kinase that regulates Mcl-1 stability is GSK3β. We and another group reported that GSK3 interacts with and phosphorylates Mcl-1 at S155, S159, and T163 (Maurer et al., [@B71]; Ding et al., [@B32]). In addition, phosphorylated Mcl-1 is ubiquitinated and undergoes proteasome-dependent degradation. So far, three possible ubiquitin ligases have been identified for Mcl-1. Mule is the BH3 domain-containing E3 ligase that was the first identified as the Mcl-1 ubiquitin ligase by biochemical purification (Zhong et al., [@B113]). Later, we found that β-TrCP can ubiquitinate and induce Mcl-1 degradation in GSK3β-mediated-phosphorylation-dependent manner (Ding et al., [@B32]). Recently, a tumor suppressor protein, FBW7, is shown to function as a Mcl-1 ubiquitin ligase (Inuzuka et al., [@B51]; Wertz et al., [@B105]). FBW7-induced ubiquitination of Mcl-1 is also dependent the phosphorylation induced by GSK3β. Although both β-TrCP and FBW7 recognize the same GSK3β-mediated phosphorylation sites in Mcl-1, the exact roles of these two ubiquitin ligases under various apoptotic stresses are unknown.

AKT and ERK have been shown to upregulate Mcl-1 transcription (Wang et al., [@B101]; Booy et al., [@B11]). In addition, both PI3K/AKT and MEK/ERK pathways have also been shown to enhance Mcl-1 protein stability (Derouet et al., [@B30]). Because AKT inhibits GSK3β as described above, AKT increases Mcl-1 stability, at least in part, by inhibiting GSK3β. Indeed, the inhibition of PI3K induces S159 phosphorylation of Mcl-1 and subsequent ubiquitination and degradation of Mcl-1, which are blocked by GSK3 inhibition (Maurer et al., [@B71]). In addition to GSK3β, it has been show that ERK phosphorylates Mcl-1 at T92 and T163 (Domina et al., [@B35]; Ding et al., [@B33]). In particular, we showed that ERK-phoshorylated Mcl-1 can interact with Pin1 (Ding et al., [@B33]). Pin1 is a peptidyl--prolyl *cis*/*trans* isomerase that binds to specific pS/T-P motifs and then isomerizes its substrates, resulting in their conformational changes. Interestingly, Pin1 stabilizes Mcl-1 protein after the phosphorylation by ERK, and the expression of Mcl-1 correlates with Pin1 in multiple human cancer cell lines (Ding et al., [@B33]). Thus, ERK and Pin1 cooperatively regulate Mcl-1 stability. Regarding IKK, there is no evidence that IKK is directly involved in Mcl-1 or GSK3β phosphorylation and/or ubiquitination. However, it has been shown that NF-κB is required for EGF-induced Mcl-1 induction, suggesting that the IKK--NF-κB pathway plays a role in Mcl-1 expression or stability (Henson et al., [@B42]). Thus, Mcl-1 is a critical apoptosis regulator that is controlled by the three kinases at the post-translational as well as transcriptional level (Figure [2](#F2){ref-type="fig"}A).

![**Regulation of Mcl-1 and Snail by AKT, ERK, and IKK signaling pathway**. **(A)** AKT and ERK phosphorylates GSK3β and inhibit it. GSK3β phosphorylates Mcl-1 and induces its ubiquitination and subsequent degradation via β-TrCP, Mule, and/or FBW7. ERK also directly phosphorylates Mcl-1, and phosphorylated Mcl-1 interacts with Pin1, resulting in its stabilization. The IKK--NF-κB pathway also contributes to Mcl-1 upregulation but the mechanisms are uncertain. **(B)** AKT and ERK phosphorylates GSK3β and inhibit it. GSK3β phosphorylates Snail and induces its nuclear exclusion, ubiquitination and subsequent degradation via β-TrCP. ERK also upregulates Snail transcription via AP-1 transcription factor. The IKK--NF-κB pathway inhibits Snail via upregulation of CSN2, which interferes with the GSK3--Snail interaction and ubiquitination of Snail.](fonc-02-00015-g002){#F2}

Snail
=====

Epithelial--mesenchymal transition (EMT) is an important physiological process that converts epithelial cells to mesenchymal cells which plays an essential role in embryonic development and tissue repair (Nieto, [@B75]). In addition, accumulating evidence shows that EMT is also critical for cancer metastasis. Epithelial cells lose cell--cell contacts and gain migratory properties during EMT. During cancer progression, cancer cells undergo EMT, resulting in increased motility, invasiveness, and aggressive behavior (Kalluri and Weinberg, [@B54]). Snail is a zinc-finger transcription repressor that is one of the EMT regulators. Snail family contains Snail1 (Snail), Snail2 (Slug), and Snail3 (Smuc; de Herreros et al., [@B29]). Like other EMT regulators, Snail suppresses E-cadherin expression by binding to its promoter. In addition to EMT, Snail is also involved in cell death, survival, stem cell, and immune regulation by controlling multiple target genes (Wu and Zhou, [@B108]). Downregulation of Snail reduces tumor growth and invasiveness in xenograft animal model (Olmeda et al., [@B77]). Moreover, Snail is overexpressed in multiple human cancers, and expression of Snail is associated with poor cancer prognosis (Peinado et al., [@B80]). Therefore, Snail is a critical oncogenic factor.

Snail stability is primarily regulated by GSK3β through the PI3K--AKT pathway (Song et al., [@B90]). We have shown that GSK3β can phosphorylate Snail at six serine residues in which two of them are responsible for Snail stability while the other four are involved in its nuclear localization (Zhou et al., [@B114]). First, GSK3β phosphorylates Snail at four serine residues to allow its export from the nucleus. Then, GSK3β phosphorylates the other two sites, resulting in β-TrCP-mediated ubiquitination and degradation of Snail. IKK--NF-κB pathway has also been shown to regulate Snail stability. Specifically, NF-κB induces COP9 signalosome 2 (CSN2), which disrupts the interaction between GSK3 and Snail, resulting in the inhibition of Snail ubiquitination and subsequent degradation (Wu et al., [@B107]). So far, there is no evidence to show that MEK--ERK signaling pathway is directly involved in Snail stability. However, ERK does play a role in c-Myc-induced EMT via the inhibition of GSK3β, and there by stabilizing Snail (Cho et al., [@B21]). Furthermore, ERK upregulates Snail gene transcription though activation of AP-1 transcription factor (Hudson et al., [@B48]; Li et al., [@B60]). Independently of kinases, wild type p53 but not mutant p53 has been shown to interact with and induce Snail and Slug ubiquitination and degradation (Wang et al., [@B102]; Lim et al., [@B62]). MDM2 functions as an ubiquitin ligase for p53-induced Snail ubiquitination. Moreover, F-box and leucine-rich repeat protein 14 (FBXL14) has been shown to interact with and induce Snail ubiquitination and degradation (Vinas-Castells et al., [@B100]). So far, no other kinases have been reported to be involved in MDM2- or FBXL-mediated Snail ubiquitination. Thus, the three kinases (AKT, ERK, and IKK) seem to be involved in EMT, at least in part, by regulating Snail expression through ubiquitination (Figure [2](#F2){ref-type="fig"}B).

Conclusion and Future Prospect
==============================

Recent advances in signal transduction studies have identified many key oncogenic kinases and their substrates in cancer progression, and the signaling pathways associated with these kinases have been recognized as promising drug targets. Indeed, several kinase inhibitors have been developed and used in clinic that show high efficacy and low toxicity (Sharma and Settleman, [@B88]). However, several clinical studies have emerged showing that some patients exhibit little or no response to these targeted drugs, and those who originally responded the drugs eventually developed resistance. Although the detailed mechanisms underlying drug resistance are not fully understood, there is evidence to support that alternative pathways are being activated in resistant cells to compensate for the survival signal blocked by targeting agents. For example, EGFR tyrosine kinase inhibitors (TKIs) are effective drugs for EGFR mutant lung cancer, but c-MET amplification or K-Ras mutation causes the resistance to TKIs by bypassing the inhibition of survival signaling (Bean et al., [@B9]; Linardou et al., [@B64]). We also showed that cancer cells with high AKT signaling pathway exhibit resistance to ERK inhibitors by inhibiting FOXO3 (Yang et al., [@B109]). Therefore, in order to develop effective personalized cancer therapy, it would be essential that we understand the cross-talk among the multiple oncogenic signaling pathways.

In this review, we introduced AKT, ERK, and IKK as the key survival kinases for cancer progression and survival. We also mentioned that these three pathways have several common targets that are critical for cancer cell proliferation, survival, and EMT. Because there are many other pathways that are activated in human cancers, we believe that they likely also contribute to the same targets we described here. These three kinase-signaling pathways may have other common targets that are critical for cancer progression. We also introduce some examples of the signaling pathways that are controlled via the ubiquitin--proteasome system, which seems to play an essential role in signaling pathway like phosphorylation. As we described above, inhibition of protein ubiquitination has been demonstrated to be potential drug targets for cancer therapy. Moreover, blockade of specific ubiquitination may exhibit less toxicity because inhibition of upstream molecules in key oncogenic signaling pathways may affect numerous signaling pathways and induce unfavorable side effects. Clearly, further studies for signaling pathways in cancer including post-translational modifications are required for the development of effective personalized cancer therapies.
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